Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140413 · ClinicalTrials.gov registry record · Phase 4
Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
A Phase 4 study of Growth Hormone Deficiency and Hypopituitarism, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00140413 is a Phase 4 study of Growth Hormone Deficiency and Hypopituitarism that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 20 participants, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00140413, a Phase 4 study of Growth Hormone Deficiency and Hypopituitarism, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypotheses: 1. The prevalence of endocrinopathies, and growth hormone (GH) deficiency in particular, among young children diagnosed with optic nerve hypoplasia (ONH) is higher than is commonly thought. 2. Early treatment of children with ONH and GH-deficiency can prevent adverse outcomes. Aims: 1. Determine the prevalence and types of endocrinopathies in children diagnosed with ONH. 2. Correlate endocrine outcome with radiographic, ocular, and developmental findings in children with ONH. 3. Examine the effect of GH treatment on growth and obesity in children with ONH, GH-deficiency, and either subnormal or normal growth compared to children with ONH that are not GH-deficient. 4. Compare growth outcomes between children with isolated GH-deficiency and those with multiple hormone deficiencies.
Conditions Studied
Interventions
- DRUG Nutropin AQ
Study Locations (1)
California
- Childrens Hospital Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140413
The ClinicalTrials.gov registry entry for NCT00140413 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (95% lower). The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Nutropin AQ is the first listed.
NCT00140413 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00140413 about?
NCT00140413 is a clinical study titled "Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia". Hypotheses: 1. The prevalence of endocrinopathies, and growth hormone (GH) deficiency in particular, among young children diagnosed with optic nerve hypoplasia (ONH) is higher than is commonly thought. 2. Early treatment of children with ONH and GH-deficiency can prevent adverse outcomes. Aims: 1...
What is the current status of trial NCT00140413?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2004-12. Estimated completion is 2014-02.
What conditions does trial NCT00140413 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency, Hypopituitarism, Septo-Optic Dysplasia.
What interventions are being tested in trial NCT00140413?
The interventions under investigation include: Nutropin AQ (DRUG).
Who is sponsoring clinical trial NCT00140413?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00140413 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
COMPLETED · Phase 4
-
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
RECRUITING
-
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
RECRUITING
-
Chromosome 18 Clinical Research Center
RECRUITING
-
Growth Hormone Replacement Therapy for Retried Professional Football Players
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.